Key result
Robotic mitral valve replacement shows similar 5-year mortality to conventional sternotomy while shortening hospital stays.
Why the study?
The study was conducted to compare early and medium-term outcomes between robotic and sternotomy approaches for mitral valve replacement.
Does robotic mitral valve replacement improve early and medium-term outcomes compared to conventional sternotomy in patients undergoing MVR?
Cohort (n=1,393)
No
Does robotic mitral valve replacement improve early and medium-term outcomes compared to conventional sternotomy in patients undergoing MVR?
Hazard Ratio: 0.831 (95% CI 0.388–1.777)
Absolute Event Rate: 5.4% vs 6.5%
p-value: p=0.633
Robotic mitral valve replacement offers similar early and medium-term safety and efficacy to conventional sternotomy, with the added benefits of shorter ICU and hospital stays.
May favor robotic MVR for shorter recovery in experienced centers; leaves open need for RCTs to confirm equivalence.
To compare early and medium-term outcomes between robotic and sternotomy approaches for mitral valve replacement (MVR). Clinical data of 1393 cases who underwent MVR between January 2014 and January 2023 were collected and stratified into robotic MVR (n = 186) and conventional sternotomy MVR (n = 1207) groups. The baseline data of the two groups of patients were corrected by the propensity score matching (PSM) method. After matching, the baseline characteristics were not significant different between the two groups (standardized mean difference < 10%). Moreover, the rates of operative mortality (P = 0.663), permanent stroke (P = 0.914), renal failure (P = 0.758), pneumonia (P = 0.722), and reoperation (P = 0.509) were not significantly different. Operation, CPB and cross-clamp time were shorter in the sternotomy group. On the other hand, ICU stay time, post-operative LOS, intraoperative transfusion, and intraoperative blood loss were shorter or less in the robot group. Operation, CPB, and cross-clamp time in robot group were all remarkably improved with experience. Finally, all-cause mortality (P = 0.633), redo mitral valve surgery (P = 0.739), and valve-related complications (P = 0.866) in 5 years of follow-up were not different between the two groups. Robotic MVR is safe, feasible, and reproducible for carefully selected patients with good operative outcomes and medium-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2023) conducted a cohort in Mitral valve disease (n=1,393). Robotic mitral valve replacement vs. Conventional sternotomy mitral valve replacement was evaluated on 5-year all-cause mortality (HR 0.831, 95% CI 0.388-1.777, p=0.633). Robotic mitral valve replacement resulted in similar 5-year all-cause mortality compared to conventional sternotomy (HR 0.831, 95% CI 0.388-1.777, P=0.633), while significantly reducing ICU and postoperative hospital stay times.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: